IM Cannabis Past Earnings Performance
Past criteria checks 0/6
IM Cannabis's earnings have been declining at an average annual rate of -9.7%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 31.3% per year.
Key information
-9.7%
Earnings growth rate
11.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 31.3% |
| Return on equity | -334.4% |
| Net Margin | -25.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Slammed 28% IM Cannabis Corp. (CSE:IMCC) Screens Well Here But There Might Be A Catch
Sep 13
A Piece Of The Puzzle Missing From IM Cannabis Corp.'s (CSE:IMCC) Share Price
Jul 30Potential Upside For IM Cannabis Corp. (CSE:IMCC) Not Without Risk
Jul 19Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?
Dec 24Don't Ignore The Fact That This Insider Just Sold Some Shares In IM Cannabis Corp. (CSE:IMCC)
Feb 05
What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?
Jan 08Revenue & Expenses Breakdown
How IM Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 51 | -13 | 18 | 0 |
| 30 Jun 24 | 50 | -14 | 19 | 0 |
| 31 Mar 24 | 48 | -15 | 20 | 0 |
| 31 Dec 23 | 49 | -9 | 22 | 0 |
| 30 Sep 23 | 53 | -15 | 18 | 0 |
| 30 Jun 23 | 54 | -17 | 21 | 0 |
| 31 Mar 23 | 54 | -17 | 23 | 0 |
| 31 Dec 22 | 54 | -23 | 24 | 0 |
| 30 Sep 22 | 50 | -22 | 32 | 0 |
| 30 Jun 22 | 44 | -16 | 32 | 0 |
| 31 Mar 22 | 38 | -10 | 30 | 0 |
| 31 Dec 21 | 34 | 0 | 29 | 0 |
| 30 Sep 21 | 29 | -10 | 27 | 0 |
| 30 Jun 21 | 27 | -12 | 23 | 0 |
| 31 Mar 21 | 23 | -24 | 23 | 0 |
| 31 Dec 20 | 16 | -29 | 19 | 0 |
| 30 Sep 20 | 13 | -7 | 14 | 0 |
| 30 Jun 20 | 10 | -10 | 13 | 0 |
| 31 Mar 20 | 8 | -1 | 11 | 0 |
| 31 Dec 19 | 9 | -7 | 10 | 0 |
| 30 Sep 19 | 8 | -8 | 9 | 0 |
| 30 Jun 19 | 7 | -6 | 7 | 0 |
| 31 Mar 19 | 6 | -6 | 5 | 0 |
| 31 Dec 18 | 5 | 2 | 3 | 0 |
| 31 Dec 17 | 4 | 1 | 2 | 0 |
Quality Earnings: IMCC is currently unprofitable.
Growing Profit Margin: IMCC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMCC is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare IMCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMCC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: IMCC has a negative Return on Equity (-334.39%), as it is currently unprofitable.